On October 9, 2025, Expedition Therapeutics, a biotech company developing therapies for novel inflammatory and respiratory diseases, announced the closing of an oversubscribed $165 million Series A financing. The round was co-led by Sofinnova Investments and Novo Holdings, with additional investment from Forbion, Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing investors BVF Partners and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati advised co-lead investors Sofinnova and Novo Holdings, as well as syndicate investor Forbion, on the transaction.

Proceeds from the funding will be used to support indication expansion and advance Expedition’s lead candidate, EXPD-101, through a global Phase 2 study in chronic obstructive pulmonary disease (COPD).

The Wilson Sonsini team that advised Sofinnova, Novo Holdings, and Forbion included:

Corporate    
Dan Koeppen
Kassandra Castillo
James Keegan

Patents and Innovations                            
Michael Hostetler
Val Zunic

Technology Transactions
Lowell Segal 

National Security
Stephen Heifetz

For more information, please see Expedition Therapeutics’ press release.